Activating c-KIT mutations confer oncogenic cooperativity and rescue RUNX1/ETO-induced DNA damage and apoptosis in human primary CD34+ hematopoietic progenitors

Leukemia

Volumn 29, Issue 2, 2015, Pages 279-289

  Wichmann, C ^a,b   Quagliano Lo Coco, I ^a   Yildiz, O ^a   Chen Wichmann, L ^a,b   Weber, H ^a,c   Syzonenko, T ^a   Doring C ^d   Brendel, C ^a   Ponnusamy, K ^b,d   Kinner, A ^a   Brandts, C ^d   Henschler, R ^b,d   Grez, M ^a  

^a INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSIDAD DE LA FRONTERA   (Chile)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 2 MORPHOLINO 8 PHENYLCHROMONE; CD34 ANTIGEN; DAUNORUBICIN; ETO PROTEIN; HYBRID PROTEIN; IMATINIB; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; AML1-ETO FUSION PROTEIN, HUMAN; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR; ONCOPROTEIN; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROTECTION; CLONOGENESIS; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; DRUG MECHANISM; EX VIVO STUDY; EXHAUSTION; GENE AMPLIFICATION; GENE MUTATION; HEMATOPOIETIC STEM CELL; HOMOLOGOUS RECOMBINATION; HUMAN; HUMAN CELL; ONCOGENE C KIT; PHENOTYPE; PRIORITY JOURNAL; CELL CYCLE; CELL SEPARATION; CHEMISTRY; CHROMOSOME 21; CHROMOSOME 8; CYTOLOGY; FLOW CYTOMETRY; GENE TRANSLOCATION; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR CLONING; MUTATION; PROTEIN TERTIARY STRUCTURE; U937 CELL LINE;

ANTIGENS, CD34; APOPTOSIS; BENZAMIDES; CELL CYCLE; CELL SEPARATION; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; CLONING, MOLECULAR; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA DAMAGE; DNA REPAIR; DOWN-REGULATION; ENZYME INHIBITORS; FLOW CYTOMETRY; HEK293 CELLS; HEMATOPOIETIC STEM CELLS; HUMANS; IMATINIB MESYLATE; MUTATION; ONCOGENE PROTEINS, FUSION; PHENOTYPE; PIPERAZINES; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; TRANSLOCATION, GENETIC; U937 CELLS;

EID: 84922560582     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.179     Document Type: Article

References (53)

1. Yan M, Burel SA, Peterson LF, Kanbe E, Iwasaki H, Boyapati A et al. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development. Proc Natl Acad Sci USA 2004; 101: 17186-17191.
2. Wildonger J, Mann RS. The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor. Development 2005; 132: 2263-2272.
3. Ptasinska A, Assi SA, Mannari D, James SR, Williamson D, Dunne J et al. Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding. Leukemia 2012; 26: 1829-1841.
4. Song J, Mercer D, Hu X, Liu H, Li MM. Common leukemia- and lymphoma-associated genetic aberrations in healthy individuals. J Mol Diagn 2011; 13: 213-219.
5. Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL et al. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood 2003; 102: 4369-4376.
6. Jiao B, Wu CF, Liang Y, Chen HM, Xiong SM, Chen B et al. AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2. Leukemia 2009; 23: 1598-1604.
7. Wang YY, Zhou GB, Yin T, Chen B, Shi JY, Liang WX et al. AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 2005; 102: 1104-1109.
8. Wakita S, Yamaguchi H, Miyake K, Mitamura Y, Kosaka F, Dan K et al. Importance of c-kit mutation detection method sensitivity in prognostic analyses of t(8;21)(q22;q22) acute myeloid leukemia. Leukemia 2011; 25: 1423-1432.
9. Wang YY, Zhao LJ, Wu CF, Liu P, Shi L, Liang Y et al. C-KIT mutation cooperates with full-length AML1-ETO to induce acute myeloid leukemia in mice. Proc Natl Acad Sci USA 2011; 108: 2450-2455.
10. Nick HJ, Kim HG, Chang CW, Harris KW, Reddy V, Klug CA. Distinct classes of c-Kitactivating mutations differ in their ability to promote RUNX1-ETO-associated acute myeloid leukemia. Blood 2012; 119: 1522-1531.
11. Lennartsson J, Ronnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev 2012; 92: 1619-1649.
12. Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002; 99: 15-23.
13. Chou FS, Wunderlich M, Griesinger A, Mulloy JC. N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene. Blood 2011; 117: 2237-2240.
14. Wichmann C, Becker Y, Chen-Wichmann L, Vogel V, Vojtkova A, Herglotz J et al. Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity. Blood 2010; 116: 603-613.
15. Stein S, Ott MG, Schultze-Strasser S, Jauch A, Burwinkel B, Kinner A et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010; 16: 198-204.
16. Epinat JC, Arnould S, Chames P, Rochaix P, Desfontaines D, Puzin C et al. A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells. Nucleic Acids Res 2003; 31: 2952-2962.
17. Team RDC. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2005. http://www.R-project.org.
18. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
19. Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006; 12: 945-949.
20. Castaigne S, Daniel MT, Tilly H, Herait P, Degos L. Does treatment with ARA-C in low dosage cause differentiation of leukemic cells? Blood 1983; 62: 85-86.
21. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol 2002; 9: 274-281.
22. Wang L, Zhao WL, Yan JS, Liu P, Sun HP, Zhou GB et al. Eriocalyxin B induces apoptosis of t(8;21) leukemia cells through NF-kappaB and MAPK signaling pathways and triggers degradation of AML1-ETO oncoprotein in a caspase-3-dependent manner. Cell Death Differ 2007; 14: 306-317.
23. Lu Y, Peng ZG, Yuan TT, Yin QQ, Xia L, Chen GQ. Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity. Leukemia 2008; 22: 378-386.
24. Zhen T, Wu CF, Liu P, Wu HY, Zhou GB, Lu Y et al. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. Sci Transl Med 2012; 4: 127ra138.
25. Burel SA, Harakawa N, Zhou L, Pabst T, Tenen DG, Zhang DE. Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation. Mol Cell Biol 2001; 21: 5577-5590.
26. Alcalay M, Meani N, Gelmetti V, Fantozzi A, Fagioli M, Orleth A et al. Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. J Clin Invest 2003; 112: 1751-1761.
27. Krejci O, Wunderlich M, Geiger H, Chou FS, Schleimer D, Jansen M et al. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood 2008; 111: 2190-2199.
28. Lu Y, Xu YB, Yuan TT, Song MG, Lubbert M, Fliegauf M et al. Inducible expression of AML1-ETO fusion protein endows leukemic cells with susceptibility to extrinsic and intrinsic apoptosis. Leukemia 2006; 20: 987-993.
29. Satoh Y, Matsumura I, Tanaka H, Harada H, Harada Y, Matsui K et al. C-terminal mutation of RUNX1 attenuates the DNA-damage repair response in hematopoietic stem cells. Leukemia 2012; 26 : 303-311.
30. Zheng X, Oancea C, Henschler R, Ruthardt M. Cooperation between constitutively activated c-Kit signaling and leukemogenic transcription factors in the determination of the leukemic phenotype in murine hematopoietic stem cells. Int J Oncol 2009; 34 : 1521-1531.
31. Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W et al. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 2005; 106: 3958-3961.
32. Foster R, Griffith R, Ferrao P, Ashman L. Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 2004; 23: 139-152.
33. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-1942.
34. Wohrle FU, Halbach S, Aumann K, Schwemmers S, Braun S, Auberger P et al. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors. Leukemia 2013; 27: 118-129.
35. Hashimoto K, Matsumura I, Tsujimura T, Kim DK, Ogihara H, Ikeda H et al. Necessity of tyrosine 719 and phosphatidylinositol 3'-kinase-mediated signal pathway in constitutive activation and oncogenic potential of c-kit receptor tyrosine kinase with the Asp814Val mutation. Blood 2003; 101: 1094-1102.
36. Lennartsson J, Ronnstrand L. The stem cell factor receptor/c-Kit as a drug target in cancer. Curr Cancer Drug Targets 2006; 6: 65-75.
37. Bertacchini J, Guida M, Accordi B, Mediani L, Martelli AM, Barozzi P et al. Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis. Leukemia 2014; 28: 2197-2205.
38. Reikvam H, Tamburini J, Skrede S, Holdhus R, Poulain L, Ersvaer E et al. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. Br J Haematol 2014; 164: 200-211.
39. Thomas D, Powell JA, Vergez F, Segal DH, Nguyen NY, Baker A et al. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood 2013; 122: 738-748.
40. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
41. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, Timms JF et al. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 2007; 404: 15-21.
42. Kumar A, Fernandez-Capetillo O, Carrera AC. Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair. Proc Natl Acad Sci USA 2010; 107: 7491-7496.
43. Ibrahim YH, Garcia-Garcia C, Serra V, He L, Torres-Lockhart K, Prat A et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triplenegative breast cancer to PARP inhibition. Cancer Discov 2012; 2: 1036-1047.
44. Kim KC, Lee IK, Kang KA, Cha JW, Cho SJ, Na SY et al. 7,8-Dihydroxyflavone suppresses oxidative stress-induced base modification in DNA via induction of the repair enzyme 8-oxoguanine DNA glycosylase-1. Biomed Res Int 2013; 2013: 863720.
45. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance. Carcinogenesis 2010; 31: 955-960.
46. Fujita J, Crane AM, Souza MK, Dejosez M, Kyba M, Flavell RA et al. Caspase activity mediates the differentiation of embryonic stem cells. Cell Stem Cell 2008; 2: 595-601.
47. Leong SM, Tan BX, Bte Ahmad B, Yan T, Chee LY, Ang ST et al. Mutant nucleophosmin deregulates cell death and myeloid differentiation through excessive caspase-6 and -8 inhibition. Blood 2010; 116: 3286-3296.
48. Huang Y, Nakada S, Ishiko T, Utsugisawa T, Datta R, Kharbanda S et al. Role for caspase-mediated cleavage of Rad51 in induction of apoptosis by DNA damage. Mol Cell Biol 1999; 19: 2986-2997.
49. Bartel Y, Grez M, Wichmann C. Interference with RUNX1/ETO leukemogenic function by cell-penetrating peptides targeting the NHR2 oligomerization domain. Biomed Res Int 2013; 2013: 297692.
50. Metz A, Schanda J, Grez M, Wichmann C, Gohlke H. From determinants of RUNX1/ETO tetramerization to small-molecule protein-protein interaction inhibitors targeting acute myeloid leukemia. J Chem Inf Model 2013; 53: 2197-2202.
51. Wichmann C, Chen L, Heinrich M, Baus D, Pfitzner E, Zornig M et al. Targeting the oligomerization domain of ETO interferes with RUNX1/ETO oncogenic activity in t(8;21)-positive leukemic cells. Cancer Res 2007; 67: 2280-2289.
52. Fang HT, Zhang B, Pan XF, Gao L, Zhen T, Zhao HX et al. Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. Proc Natl Acad Sci USA 2012; 109: 2521-2526.
53. Paschka P, Marcucci G, Ruppert AS, Mrozek K, Chen H, Kittles RA et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904-3911.